Assyro AI

Orange Book product · Brand (NDA)

AKEEGA

ABIRATERONE ACETATE; NIRAPARIB TOSYLATE

Brand (NDA)NDA 216793RX JANSSEN BIOTECH

At a glance

Aug 11, 2023

Approved

Brand (NDA)

Application

Not listed

TE code

22

Listed patents

Key dates

  1. Approval

    FDA approval date of this drug product.

    Aug 11, 2023

    2 yr 11 mo ago

  2. Today

  3. Exclusivity ends · NP

    New product exclusivity (3 years)

    Aug 11, 2026

    in 2 mo

  4. Patent 8071579 expires

    Listed method-of-use patent (U-2830) expiration.

    Aug 12, 2027

    in 1 yr 2 mo

  5. Patent 8071579 expires

    Listed method-of-use patent (U-4368) expiration.

    Aug 12, 2027

    in 1 yr 2 mo

  6. Patent 8143241 expires

    Listed method-of-use patent (U-2830) expiration.

    Aug 12, 2027

    in 1 yr 2 mo

  7. Patent 8143241 expires

    Listed method-of-use patent (U-4368) expiration.

    Aug 12, 2027

    in 1 yr 2 mo

  8. Exclusivity ends · I-980

    New indication exclusivity (3 years)

    Dec 12, 2028

    in 2 yr 6 mo

  9. Patent 8436185 expires

    Listed drug substance patent expiration.

    Apr 24, 2029

    in 2 yr 11 mo

  10. Patent 8071623 expires

    Listed drug substance patent expiration.

    Mar 27, 2031

    in 4 yr 10 mo

  11. Patent 8859562 expires

    Listed method-of-use patent (U-2830) expiration.

    Aug 04, 2031

    in 5 yr 2 mo

  12. Patent 8859562 expires

    Listed method-of-use patent (U-4368) expiration.

    Aug 04, 2031

    in 5 yr 2 mo

  13. Patent 11207311 expires

    Listed method-of-use patent (U-2830) expiration.

    Jul 28, 2037

    in 11 yr 3 mo

  14. Patent 11207311 expires

    Listed method-of-use patent (U-4368) expiration.

    Jul 28, 2037

    in 11 yr 3 mo

  15. Patent 11986468 expires

    Listed method-of-use patent (U-4368) expiration.

    Jul 28, 2037

    in 11 yr 3 mo

  16. Patent 11986468 expires

    Listed method-of-use patent (U-2830) expiration.

    Jul 28, 2037

    in 11 yr 3 mo

  17. Patent 11986469 expires

    Listed method-of-use patent (U-4368) expiration.

    Jul 28, 2037

    in 11 yr 3 mo

  18. Patent 11986469 expires

    Listed method-of-use patent (U-2830) expiration.

    Jul 28, 2037

    in 11 yr 3 mo

  19. Patent 11986470 expires

    Listed method-of-use patent (U-4368) expiration.

    Jul 28, 2037

    in 11 yr 3 mo

  20. Patent 11992486 expires

    Listed method-of-use patent (U-4368) expiration.

    Jul 28, 2037

    in 11 yr 3 mo

  21. Patent 11992486 expires

    Listed method-of-use patent (U-2830) expiration.

    Jul 28, 2037

    in 11 yr 3 mo

  22. Patent 12383543 expires

    Listed method-of-use patent (U-4368) expiration.

    Jul 28, 2037

    in 11 yr 3 mo

  23. Patent 12383543 expires

    Listed method-of-use patent (U-2830) expiration.

    Jul 28, 2037

    in 11 yr 3 mo

  24. Patent 11091459 expires

    Listed drug substance patent expiration.

    Mar 27, 2038

    in 11 yr 11 mo

  25. Patent 11673877 expires

    Listed drug substance patent expiration.

    Mar 27, 2038

    in 11 yr 11 mo

  26. Patent 11673877 expires

    Listed drug substance patent expiration.

    Mar 27, 2038

    in 11 yr 11 mo

Pharmaceutical detail

Active ingredient

ABIRATERONE ACETATE; NIRAPARIB TOSYLATE

Strength

500MG;EQ 50MG BASE

Dosage form

TABLET

Route

ORAL

TE code

Not listed

Application

NDA 216793

Product number

001

Marketing status

RX

Reference listed drug (RLD)

Yes

Reference standard (RS)

No

Active-ingredient family

View full family

This is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

Marketing exclusivity (2)

  • NPNew product exclusivity (3 years)

    Aug 11, 2026

    in 2 mo

  • I-980New indication exclusivity (3 years)

    Dec 12, 2028

    in 2 yr 6 mo

Listed patents (22)

Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
PatentExpiresInType
8071579Aug 12, 2027in 1 yr 2 mo
U-2830
8071579Aug 12, 2027in 1 yr 2 mo
U-4368
8143241Aug 12, 2027in 1 yr 2 mo
U-2830
8143241Aug 12, 2027in 1 yr 2 mo
U-4368
8436185Apr 24, 2029in 2 yr 11 mo
SubstanceProduct
8071623Mar 27, 2031in 4 yr 10 mo
SubstanceProduct
8859562Aug 04, 2031in 5 yr 2 mo
U-2830
8859562Aug 04, 2031in 5 yr 2 mo
U-4368
11207311Jul 28, 2037in 11 yr 3 mo
U-2830
11207311Jul 28, 2037in 11 yr 3 mo
U-4368
11986468Jul 28, 2037in 11 yr 3 mo
U-4368
11986468Jul 28, 2037in 11 yr 3 mo
U-2830
11986469Jul 28, 2037in 11 yr 3 mo
U-4368
11986469Jul 28, 2037in 11 yr 3 mo
U-2830
11986470Jul 28, 2037in 11 yr 3 mo
U-4368
11992486Jul 28, 2037in 11 yr 3 mo
U-4368
11992486Jul 28, 2037in 11 yr 3 mo
U-2830
12383543Jul 28, 2037in 11 yr 3 mo
U-4368
12383543Jul 28, 2037in 11 yr 3 mo
U-2830
11091459Mar 27, 2038in 11 yr 11 mo
SubstanceProduct
11673877Mar 27, 2038in 11 yr 11 mo
SubstanceProductU-2830
11673877Mar 27, 2038in 11 yr 11 mo
SubstanceProductU-4368
Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.